Karen Blomquist - P3 Health Vice Relations
| PIIIW Stock | USD 0.01 0 21.17% |
Executive
Karen Blomquist is Vice Relations of P3 Health Partners
| Address | 2370 Corporate Circle, Henderson, NV, United States, 89074 |
| Phone | 702 910 3950 |
| Web | https://p3hp.org |
P3 Health Management Efficiency
The company has return on total asset (ROA) of (0.1202) % which means that it has lost $0.1202 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4125) %, meaning that it generated substantial loss on money invested by shareholders. P3 Health's management efficiency ratios could be used to measure how well P3 Health manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.31 in 2024. Return On Capital Employed is likely to drop to -0.31 in 2024. At this time, P3 Health's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 806.1 M in 2024, whereas Intangible Assets are likely to drop slightly above 601 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Tom Huang | Sight Sciences | N/A | |
| Daniel JD | Orthopediatrics Corp | 54 | |
| Jacques Cornet | Profound Medical Corp | 68 | |
| Abbey Goodman | Profound Medical Corp | 41 | |
| Jonathan Friedman | Paragon 28 | 53 | |
| Matthew Millard | Paragon 28 | N/A | |
| Shana MBA | Nevro Corp | 51 | |
| Daniel Cher | Si Bone | 59 | |
| Nikolas Kerr | Si Bone | 52 | |
| David Crawford | Bioventus | N/A | |
| Roberto Donadello | Orthofix Medical | N/A | |
| Kashif Rashid | Nevro Corp | 50 | |
| Stephen Deitsch | Paragon 28 | 52 | |
| Katrina JD | Bioventus | 62 | |
| David Caraway | Nevro Corp | 63 | |
| Amy Treadwell | Neuropace | N/A | |
| Reay MD | Sight Sciences | N/A | |
| Hans Kestler | Paragon 28 | N/A | |
| Matt Brinckman | Paragon 28 | N/A | |
| Kelley Nicholas | Neuropace | N/A | |
| Andres Cedron | Orthofix Medical | 43 | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.12 |
P3 Health Partners Leadership Team
Elected by the shareholders, the P3 Health's board of directors comprises two types of representatives: P3 Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PIIIW. The board's role is to monitor P3 Health's management team and ensure that shareholders' interests are well served. P3 Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, P3 Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Unmesh Srivastava, Chief Officer | ||
| BSN CRNI, Chief Staff | ||
| Leslie Fisher, General Affairs | ||
| Roy Youngblood, Director Compliance | ||
| Kassi APR, Culture Communications | ||
| Todd MHA, Chief Officer | ||
| Eric Atkins, Chief Officer | ||
| Scott Keim, Chief Officer | ||
| FACEP FACP, CEO Director | ||
| William Bettermann, Executive COO | ||
| MD MBA, Chief CoFounder | ||
| Jessica Puathasnanon, General Officer | ||
| Devery Goodey, Senior Technology | ||
| Atul Kavthekar, CFO Officer | ||
| Karen Blomquist, Vice Relations | ||
| Lorie CPA, COO Chairwoman | ||
| David Yarger, Market Market | ||
| Leif Pedersen, Chief Officer | ||
| Aric MD, CEO President | ||
| Thomas Conjurski, Exec Operations |
PIIIW Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is P3 Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | (0.08) % | ||||
| Number Of Shares Shorted | 34.02 K | ||||
| Revenue | 1.27 B | ||||
| EBITDA | (81.07 M) | ||||
| Net Income | (57.77 M) | ||||
| Cash And Equivalents | 4.34 M | ||||
| Cash Per Share | 0.10 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for PIIIW Stock Analysis
When running P3 Health's price analysis, check to measure P3 Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy P3 Health is operating at the current time. Most of P3 Health's value examination focuses on studying past and present price action to predict the probability of P3 Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move P3 Health's price. Additionally, you may evaluate how the addition of P3 Health to your portfolios can decrease your overall portfolio volatility.